![headshot](https://opd-resources.mcw.edu/FileLibrary/OPD/Providers/photos/Gordon_Kenneth.jpg?w=400&h=450&mode=crop&anchor=middlecenter&scale=both 400w)
Kenneth Brian Gordon, MD
Chair, Professor
Locations
- Froedtert Hospital
- Zablocki VA Medical Center
- Dermatology, Froedtert Bluemound Clinics
Specialties
- Dermatology
Languages
- English
New & Established Patients Call
Education
- MD - Doctor of Medicine
Publications
-
Bimekizumab for the treatment of psoriasis.
(Thapar M, Patel M, Gordon K.) Immunotherapy. 2024 Apr;16(7):431-446 PMID: 38506262 SCOPUS ID: 2-s2.0-85188760913 03/20/2024
-
(Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaçi D.) Br J Dermatol. 2024 Mar 15;190(4):477-485 PMID: 37950894 SCOPUS ID: 2-s2.0-85187961316 11/11/2023
-
(Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D.) J Eur Acad Dermatol Venereol. 2024 Mar 07 PMID: 38451052 SCOPUS ID: 2-s2.0-85187120510 03/07/2024
-
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
(Burshtein J, Shah M, Zakria D, Lockshin B, Crowley J, Merola JF, Gordon K, Shahriari M, Korman NJ, Chovatiya R, Kalb R, Lebwohl M.) Dermatol Ther (Heidelb). 2024 Feb;14(2):323-339 PMID: 38340237 PMCID: PMC10891030 02/10/2024
-
(Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW.) JAMA Dermatol. 2024 Feb 01;160(2):204-209 PMID: 38117487 PMCID: PMC10733845 SCOPUS ID: 2-s2.0-85180996904 12/20/2023
-
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
(Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, Felding J, Warren RB.) Dermatol Ther (Heidelb). 2023 Dec;13(12):3031-3042 PMID: 37924462 PMCID: PMC10689637 11/04/2023
-
(Ramcharran D, Strober B, Gordon K, DeKlotz C, Fakharzadeh S, Yang YW, Swerdel J, Hardin J, Dronavalli S, Paller AS.) Adv Ther. 2023 Nov;40(11):5090-5101 PMID: 37737889 PMCID: PMC10567878 SCOPUS ID: 2-s2.0-85171796117 09/22/2023
-
(Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG.) Lancet. 2023 Oct 28;402(10412):1541-1551 PMID: 37738999 SCOPUS ID: 2-s2.0-85173148730 09/23/2023
-
(Singla S, Putman M, Liew J, Gordon K.) Lancet Rheumatol. 2023 Jun;5(6):e313 PMID: 38251598 01/22/2024
-
(Singla S, Putman M, Liew J, Gordon K.) Lancet Rheumatol. 2023 Apr;5(4):e200-e207 PMID: 38251522 01/22/2024
-
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
(Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, Felding J, Warren RB.) Dermatology and Therapy. December 2023;13(12):3031-3042 SCOPUS ID: 2-s2.0-85175655223 12/01/2023
-
Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines.
(Siegfried EC, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies OMT, Brandling-Bennett HA.) Pediatr Dermatol. 2023;40(5):789-808 PMID: 37316462 SCOPUS ID: 2-s2.0-85161815440 06/15/2023